Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
US FDA approves pre-filled version of GSK's shingles vaccine
07:35am, Thursday, 17'th Jul 2025
The U.S. Food and Drug Administration approved a pre-filled syringe version of GSK's blockbuster shingles vaccine Shingrix, providing patients a more convenient option to receive the shot, the company
US FDA Approves GSK's SHINGRIX in a Prefilled Syringe Presentation
07:00am, Thursday, 17'th Jul 2025
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe presentation of SHINGRIX (Zoster Vaccine
FDA staff raises eye damage concerns for GSK's blood cancer drug
08:51am, Tuesday, 15'th Jul 2025
The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug Blenrep, when used in combination with other treatments, may cause eye damage in
FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults
11:16am, Monday, 14'th Jul 2025
FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.
GSK seeks FDA nod for expanded use of RSV vaccine in adults
02:42am, Monday, 14'th Jul 2025
British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the use of its respiratory syncytial virus (RSV) vaccine to adults under the age
GSK begins shipping influenza vaccine doses for the 2025-26 flu season
09:13am, Thursday, 10'th Jul 2025
PHILADELPHIA--(BUSINESS WIRE)--GSK begins shipping influenza vaccine doses for the 2025-26 flu season.
GSK's Specialty Medicines Unit on a Strong Footing: Here's Why
10:20am, Wednesday, 09'th Jul 2025
GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.
GSK's Specialty Medicines Surge - Still Looks Undervalued In 2025
07:45am, Monday, 07'th Jul 2025
GSK specialty medicines grew YoY in Q1 2025. In fact, it's now their main profit engine, offsetting the weakness in their vaccine segment. Similarly, the company's oncology, HIV, and respiratory biolo
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Thursday, 03'rd Jul 2025
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
GSK counts on Blenrep rebound to drive £40bn sales goal
09:45am, Thursday, 03'rd Jul 2025
GSK PLC's (LSE:GSK, NYSE:GSK) long-term growth ambitions hinge in part on Blenrep, its treatment for multiple myeloma, a type of blood cancer. With the company aiming for more than £40 billion in ann
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:51am, Wednesday, 02'nd Jul 2025
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
US Senator investigates GSK for pulling children's asthma inhaler
09:11am, Friday, 27'th Jun 2025
Democratic U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for chil
Bharat, GSK to halve price of malaria vaccine by 2028
03:29am, Wednesday, 25'th Jun 2025
Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to $5 per dose by 2028, more than halving its current cost, they said on Wednesday.
EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch
01:16pm, Tuesday, 24'th Jun 2025
GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.
FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis
09:00am, Tuesday, 24'th Jun 2025
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte stim
